Verapamil and risk of cancer in patients with coronary artery disease

American Journal of Cardiology

Volumn 83, Issue 9, 1999, Pages 1419-1422

  Sajadieh, Ahmad ^c   Storm, Hans Henrik ^b   Hansen, Jørgen Fischer ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VERAPAMIL;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 0033135919     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00113-7     Document Type: Article

References (17)

1. Pahor M., Guralnik J.M., Ferrucci L., Corti M.C., Salive M.E., Cerhan J.R., Wallace R.B., Halvik R.J. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 348:1996;493-497.
2. Jick H., Jick S., Derby L.E., Vasilakis C., Myers M.W., Meier C.R. Calcium channel blockers and risk of cancer. Lancet. 349:1997;525-528.
3. Rosenberg L., Rao R.S., Palmer J.R., Strom B.L., Stolley P.D., Zauber A.G., Warshauer M.E., Shapiro S. Calcium channel blockers and the risk of cancer. JAMA. 279:1998;1000-1004.
4. Fitzpatrick A.L., Dalling J.R., Furberg C.D., Kronmal R.A., Weissfeld J.L. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 80:1997;1438-1447.
5. Olsen J.H., Toft Sorensen H.T., Friis S., McLaughlin J.K., Steffensen F.H., Nielsen G.L., Andersen M., Fraumeni J.F. Jr, Olsen J. Cancer risk in users of calcium channel blockers. Hypertension. 29:1997;1091-1094.
6. The effect of verapamil on mortality and major events after myocardial infarction. Am J Cardiol. 66:1990;779-785.
7. Storm H.H., Michelsen E.V., Clemmensen I.H., Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull. 44:1997;549-553.
8. Coleman M., Douglas A., Hermon C., Peto J. Cohort study analysis with a FORTRAN computer program. Int J Epidemiol. 15:1986;134-137.
9. Rothman K.J., Boise J.D. Jr. Epidemiologic Analysis with a Programmable Calculator. 1982;PB Epidemiology Resources Inc, Boston.
10. Haldane J.B.S. The estimation and significance of a ratio of frequencies. Ann Hum Genet. 20:1995;309-311.
11. Carson D.A., Riberio J.M. Apoptosis and disease. Lancet. 341:1993;1251-1254.
12. Opie L.H. Calcium channel blockers for hypertension dissecting the evidence for adverse effects . Am J Hypertens. 10:1997;565-577.
13. Gopalakrishna R., Barsky S. Tumor promotor-induced membrane bound protein kinase C regulates hematogenous metstasis. Proc Natl Acad Sci. 85:1988;612-616.
14. Balakumaran A., Campbell G.A., Molsen M.T. Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol. 76:1966;1-15.
15. Ahr H.J., Bomhard E., Enzman H., Karbe E., Mager H., Sander E., Schüler G. Calcium channel blockers and the risk of cancer a preclinical assessment . Cardiovasc Drugs Ther. 12:1998;157-169.
16. Braun S., Boyko V., Behar S., Reicher-Reiss H., Laniado S., Kaplinsky E., Goldburt U. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol. 31:1998;804-808.
17. Jonas M., Goldbourt U., Boyko V., Mandelzweig L., Behar S., Reicher-Reiss H. Nifedipine and cancer mortality ten-year follow-up of 2607 patients after acute myocardial infarction . Cardiovasc Drugs Ther. 12:1998;177-181.